Kamada (KMDA) Payables (2012 - 2026)
Kamada's (KMDA) quarterly Payables came in at $28.4 million in Q2 2026, up 13.06% on a YoY basis from $25.1 million in Q2 2025, and up 29.23% quarter-over-quarter from $21.9 million in Q1 2026.
Analysis
Kamada (KMDA) Payables (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Payables for 15 consecutive years, with $28.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Payables rose 13.06% year-over-year to $28.4 million; the trailing twelve-month figure through Jun 2026 stood at $28.4 million (up 13.06% YoY), and the FY2025 full-year result was $23.2 million, down 16.79% from the prior year.
- Payables improved to $28.4 million in Q2 2026 per KMDA's latest filing, from $21.9 million in the prior quarter.
- Across five years, Payables topped out at $37.4 million in Q4 2022 and bottomed at $11.7 million in Q1 2022.
- Historically, Payables has averaged $23.4 million across 5 years, with a median of $24.9 million in 2025.
- The widest YoY moves for Payables: up 124.4% in 2023, down 58.16% in 2023.
- Over 5 years, Payables stood at $37.4 million in 2022, then plunged by 33.21% to $25.0 million in 2023, then advanced by 11.94% to $27.9 million in 2024, then decreased by 16.79% to $23.2 million in 2025, then climbed by 21.98% to $28.4 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $28.4 million, $21.9 million, and $23.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 25.08 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 28.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.35 Mn |
| Mar 31, 2026 | 21.94 Mn |
| Dec 31, 2025 | 23.24 Mn |
| Sep 30, 2025 | 24.88 Mn |
| Jun 30, 2025 | 25.08 Mn |
| Mar 31, 2025 | 24.85 Mn |
| Dec 31, 2024 | 27.93 Mn |
| Sep 30, 2024 | 14.79 Mn |
| Jun 30, 2024 | 19.53 Mn |
| Mar 31, 2024 | 16.49 Mn |
| Dec 31, 2023 | 24.95 Mn |
| Sep 30, 2023 | 12.81 Mn |
| Jun 30, 2023 | 32.41 Mn |
| Mar 31, 2023 | 26.21 Mn |
| Dec 31, 2022 | 37.36 Mn |
| Sep 30, 2022 | 30.62 Mn |
| Jun 30, 2022 | 17.95 Mn |
| Mar 31, 2022 | 11.68 Mn |
| Dec 31, 2021 | 25.10 Mn |
| Sep 30, 2021 | 19.01 Mn |